Study of S-1 Oxaliplatin (SOX) for Biliary Tract Cancer (BTC) (Ampullary Adenocarcinoma)

Biliary Tract Cancer Clinical Trial

Official title:

An Pilot Study of S-1 Combined With Oxaliplatin for First-line Treatment of Unresectable, Metastatic or Locally Advanced Biliary Tract Cancer or Ampullary Adenocarcinoma

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT01180153
• Other study ID #: ChinaBJCH_SOX_BTC
• Status: Not yet recruiting
• Phase: Phase 2
• First received: August 9, 2010
• Last updated: August 11, 2010
• Start date: August 2010
• Est. completion date: August 2012

Study information

• Verified date: August 2010
• Source: Beijing Cancer Hospital
• Contact: Jie Li, Doctor
• Phone: 010-88121122
• Email: xiaotong10241[@]sina.com
• Is FDA regulated: No
• Health authority: China: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

To evaluate efficacy and safety of S-1 Oxaliplatin (SOX) regimen to patients with unresectable, metastatic or locally advanced biliary tract or ampullary adenocarcinoma.

Description:

To list in cases with unresectable, metastatic or locally advanced biliary tract or ampullary adenocarcinoma that have not been treated before,confirm the efficacy and safety of combined S-1/L-OHP regimen for the biliary tract or ampullary carcinoma, providing evidence-based proof for the future treatment.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 40
• Est. completion date: August 2012
• Est. primary completion date: August 2012
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 74 Years

Eligibility

Inclusion Criteria:

1. Informed consent has been signed by the subject itself;

2. Aged over 18;

3. With a definite pathological or cytological diagnosis of adenocarcinoma;

4. No pre-treatment (including radiotherapy, chemotherapy, immunotherapy, etc.). For recurrent cases, if the subjects have received adjuvant chemotherapy without S-1 or L-OHP after surgery and the time to the end date of adjuvant chemotherapy is over 6 months, they can also be enrolled;

5. Enhanced helical CT or MRI scanning shows a target lesion over 1cm within 14 days before enrollment

6. Within 7 days before enrollment, baseline blood routine and biochemical indicators meet the following criteria:

• Hemoglobin = 90g/L,

• Absolute neutrophil count (ANC) = 1.5 × 109/L,

• Platelets = 100×109/L,

• Serum total bilirubin < 1.5 times of the upper normal limit,

• Serum creatinine < upper limit of normal,

• Serum albumin = 30 g/L;

7. Can receive oral administration;

8. Karnofsky(KPS) score = 70 points;

9. Expected survival time is more than 90 days;

10. Women of childbearing age must receive urine or blood pregnancy test within 7 days before randomization and the results are negative;

11. Male and female patients of appropriate reproductive age are willing to use reliable contraception methods for contraception in the process of study till 30 days after drug withdrawal.

Exclusion Criteria:

1. Patients with a severe drug allergy history (including mildly allergic to L-OHP, 5-FU, FT207, 5-HT3 receptor antagonist);

2. Patients who participated or are participating in other clinical trials within 4 weeks before enrollment;

3. Patients who have received blood transfusion, blood products and hematopoietic factor preparations such as G-CSF within 15 days before enrollment;

4. Patients who have undergone a surgery within 15 days before enrollment, and its effects have not been eliminated;

5. Patients with diarrhea;

6. Patients with a complication of active infection (infection causes a fever above 38 ?);

7. Patients accompanied by dysphagia, complete or incomplete gastrointestinal obstruction, active gastrointestinal bleeding and perforation, etc. that cause difficulty in taking S-1 orally;

8. Patients with severe liver disease (e.g. active hepatitis, cirrhosis, etc.), renal insufficiency, severe lung disease (interstitial pneumonia, pulmonary fibrosis, severe emphysema, etc.), or uncontrollable diabetes, hypertension and other chronic systemic diseases;

9. Patients who have received long-term systemic steroid therapy (Note: short-term users with steroid withdrawal > 2 weeks can be selected);

10. Patients with brain metastases or suspected of brain metastases;

11. Patients with peripheral nervous system disorder or a history of significant mental disorder and central nervous system disorder;

12. Heart disease of significant clinical symptoms, e.g. congestive heart failure, coronary heart disease with significant symptoms, arrhythmia and hypertension that are difficult to be controlled by drugs, or with an episode of myocardial infarction within 6 months, or cardiac insufficiency;

13. Patients with pleural effusion, ascites, or pericardial effusion that needs drainage;

14. Pregnant or breast-feeding women, or male and female patients of appropriate reproductive age who refuse to take contraceptive measures;

15. Patients who have suffered from other malignancies within 5 years, except basal cell carcinoma and carcinoma in situ of uterine cervix that have already been cured;

16. Patients without legal capability, or who can not continue the study due to medical or ethical reasons;

17. Patients who are determined not suitable to participate in this clinical trial by the investigators.

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Adenocarcinoma
• Biliary Tract Cancer
• Biliary Tract Neoplasms

Intervention

Drug:
• S-1 oxaliplatin
S-1 (20mg, 25mg); L-OHP (50 mg)

Locations

Country	Name	City	State
China	Chin Beijing Cancer Hospital	Beijing	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
Beijing Cancer Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	objective response rate	to evaluate objective response rate (ORR) of SOX regimen to BTC (Ampullary Adenocarcinoma)	2 years	No
Secondary	overall survival	to evaluate survival data of overall survival (OS),Progression free Survival(PFS), safety outcome of SOX regimen to BTC (Ampullary Adenocarcinoma)	2 years	Yes